Professor Michaela Rumlová, head of a research group of the National Institute of Virology and Bacteriology at UCT Prague (and Vice-Rector for doctoral studies), holder of a licensed patent &nbsp;for antiretroviral testing assays, and recipient of the Czech Science Foundation’s President’s Award for HIV research, has also become the principal investigator of the bilateral INTER-EXCELLENCE II project “Cellular factors regulating the export and packaging of unspliced ​​retroviral RNA”, starting this year. In this interview, she explains how retroviruses such as HIV “hack” the cell in order to export their own genome from the nucleus into the cytoplasm, and then to the site where it is specifically packaged into nascent viral particles, a key step in viral replication. Her team is collaborating with the NIH (National Institutes of Health) and Rockefeller University to elucidate mechanisms that may help reveal new vulnerable points in the retrovirus replication cycle while simultaneously clarifying related cellular processes.<h5>Could you describe your project and its main objectives?</h5>Retroviruses, such as HIV, are viruses that carry genetic information in the form of RNA; however, after entering a cell, they are able to reverse transcribe it into DNA and integrate it into the host genome. In order to replicate, they must transport their genetic information—in the form of unspliced RNA—from the nucleus into the cytosol. There, it serves both as a template for the production of viral proteins and as the genome of new viral particles. This is highly unusual, as the cell very carefully controls which RNA molecules are allowed to leave the nucleus. Normal protein-coding cellular RNAs, known as messenger RNAs (mRNAs), must undergo splicing—a processing step in which certain segments are removed—before being exported. When this process fails, mRNA that retains these segments is held back in the nucleus as part of quality control and subsequently degraded. Retroviruses have managed to outwit this cellular control machinery, allowing their unspliced RNA to pass into the cytoplasm.Our project focuses on identifying the cellular proteins that assist retroviruses in this step and on the mechanism by which protein complexes bound to viral RNA are remodelled during RNA transport. The goal is to understand how the virus uses cellular mechanisms to its advantage and how this pathway is linked to the subsequent fate of the RNA, i.e. to its translation and packaging into new viral particles.<h5>Why is this export of unspliced ​​RNA so important for retroviral replication?</h5>Because this RNA has a dual role for the virus. On the one hand, it serves as a template for synthesizing viral proteins in the cytoplasm; on the other, it represents the genetic material itself, which must be packaged into new viral particles. The virus must package its RNA genome in its unspliced form, as only this RNA contains essential sequences without which further viral replication would be impossible.Simply put: the virus needs to get a complete copy of its genetic instructions out of the nucleus. Once the viral RNA is in the cytoplasm, it can be used as a template for synthesizing viral proteins; and a portion of these RNA molecules is then selected and packaged into a new particle as a genome. We are interested in how the virus forces the cell to allow viral RNA that is, from the cell’s perspective, “unfinished,” that is unspliced, to leave the nucleus. We are also investigating how the cell and the virus together - albeit unintentionally from the cell’s perspective - determine which RNA molecule will be translated into proteins and which will be packaged as the genome. This is one of the key, yet still not fully understood, steps of retroviral replication.<h5>What do you think it was about your project that impressed the Ministry of Education, Youth and Sports’ jury the most?</h5>I believe the decisive factor was a combination of several elements. First, the reviewers were primarily interested in the scientific problem itself. We are investigating a mechanism that is essential for retroviruses, but still not sufficiently understood, which may also have broader implications for the regulation of cellular processes. In addition, the quality of the team, our strong collaboration with the NIH and Rockefeller University, and the use of modern methods that will allow us to track viral RNA in great detail also played a role. It was also important that the project has clear objectives and a realistic plan.<h5>How will this research contribute to the development of new treatments for retroviral infections?</h5>It is important to say that this is primarily basic research. Rather than developing a new drug directly, we are trying to understand, at the molecular level, the step that the virus cannot do without. Only when we fully understand the mechanism of these cellular processes and identify the essential factors for the export of unspliced ​​RNA and how they function, will we be able to better determine which interactions or mechanisms represent potentially vulnerable points. Similar mechanisms associated with the export of unspliced ​​mRNA also appear in some diseases, such as cancer, so I &nbsp;see the benefit of our research mainly in that it will refine our understanding of these pathological processes in the cell, and retroviruses help us do so. Therefore, our work on retroviruses not only shows us how the virus works, but also how the cell itself works.<h5>What responsibilities does your UCT Prague team have? How does the collaboration with your American partners work?</h5>At UCT Prague, we are conducting the project’s primary experimental work. Our research involves cell cultures, viral models, and various biochemical techniques ranging from immunochemistry to microscopy that allow us to track viral RNA and identify its cellular partners. In collaboration with colleagues from NIH, Frederick, we are developing single-particle tracking methods to observe viral RNA movement in living cells across both space and time. Furthermore, we are working with colleagues from Rockefeller University to employ iCLIP methods for the precise mapping of protein-binding sites on RNA. Both collaborations are valuable to us, because they are not just about data sharing, but also about the transfer of expertise and detailed know-how.<h5>Who else is collaborating on the project?</h5>At UCT Prague, we collaborate closely with the Department of Biotechnology and the Department of Biochemistry and Microbiology. Externally, we work with colleagues from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague) and the Central European Institute of Technology in Brno (CEITEC). Our research naturally necessitates the integration of diverse fields of expertise; it requires combining virology, cell biology, and biochemistry with advanced imaging and modern approaches to study RNA-protein interactions. This is exactly what makes our project capable of addressing complex questions that a single laboratory cannot tackle on its own.<h5>Are there plans to continue the project? Have you brought on new collaborators, and are you looking to welcome new colleagues to the team?</h5>Yes, definitely. In basic research, it often happens that one answered question opens up several more. High-quality, properly interpreted data provide a foundation you can build on — and that is what moves scientists forward. It is already clear that the topic of retroviral RNA export and packaging has broader implications and may reveal more general principles of how RNA functions within the cell. We also hope the project will be attractive to students, as it connects classical molecular biology, biochemistry, and virology with cutting-edge biotechnological methods. Students are already involved in the project as part of their bachelor’s and master’s theses.<h5>What was the personal turning point that motivated you to pursue a long-term investigation into retroviral particles?</h5>I first encountered retroviruses in the early 1990s during my diploma thesis, when I was working at IOCB Prague on HIV-1 protease inhibitors. At that time, AIDS could not yet be effectively treated, and retrovirus research had a completely different dimension. From the very beginning, I was fascinated by how such a relatively small and simple virus can outsmart evolutionarily highly optimized cellular processes and turn them to its own advantage. And that has never stopped fascinating me. From a scientific point of view, retroviruses are remarkable; just consider one of their enzymes, reverse transcriptase, without which no diagnostic or research laboratory in the world could function today. Without it, it would be impossible to diagnose RNA viruses like SARS-CoV-2, influenza, or HIV using RT-PCR tests, or, for example to produce recombinant human proteins in bacterial cells.

Tracking unspliced RNA: Professor Rumlová studies how retroviruses “hack” cells

News from LabRulezLCMS Library - Week 20, 2026

🎤Lindsay Repka&nbsp;Lindsay Repka is a chemistry professor at Middlebury College whose research explores photoredox chemistry, catalyst stability, and visible-light-driven transformations. Her lab emphasizes both mechanistic insight and hands-on student training in advanced analytical instrumentation.In this episode of Concentrating on Chromatography, we sit down with Lindsay Repka to discuss how LC-MS and GC-MS transformed her lab’s approach to photoredox chemistry.What began as a project to develop a visible-light photocrosslinking handle unexpectedly led to a major discovery: the solvent (DMF) was reacting with the photocatalyst itself. Using high-resolution LC-MS, Lindsay’s team observed multiple solvent adducts forming — sometimes with complete catalyst consumption. That discovery reshaped their research direction.This episode is a rare deep dive into both LC-MS and GC-MS within the same research project, showing how chromatography-driven insight can turn unexpected degradation into productive new reactivity.If you work in:<ul><li>Photoredox chemistry</li><li>Reaction optimization</li><li>Mass spectrometry method development</li><li>Catalyst screening</li><li>Academic synthetic chemistry</li></ul>…this conversation will resonate.<h4>Key Topics Covered</h4><ul><li>Photocatalyst stability in DMF, DCE, and MeCN</li><li>Demethylation under mild visible-light conditions</li><li>High-resolution Q-TOF LC-MS quantitation</li><li>Internal standard methodology in GC-MS</li><li>Signal-to-noise improvement using extracted ion chromatograms</li><li>Reaction reproducibility and quality control strategy</li></ul><h3>Video Transcription</h3>In this interview, Lindsay Repka discusses the role of photoredox chemistry in method development, photocrosslinking, solvent activation, catalyst stability, and the use of LC-MS and GC-MS to understand reaction pathways.<h4>What is photoredox chemistry?</h4>Photoredox chemistry uses light to activate a photocatalyst, which can either donate or accept an electron from a substrate. This generates radical species that can undergo new types of reactivity.Repka explains that one of the key advantages of photoredox chemistry is its ability to operate under mild conditions, often using visible light. This makes it attractive for sensitive molecules and biological systems, including potential applications in drug release, live-cell chemistry, and drug development.<h4>Photocrosslinking and drug-target interactions</h4>Repka’s group initially aimed to develop visible-light photocrosslinking methods to study drug interactions with biological targets. Photocrosslinking can covalently link a drug to its target, making it easier to identify the biological target of a compound.Traditional photocrosslinking often uses UV light, but visible light offers milder and more biologically compatible conditions.<h4>From photocrosslinking to solvent activation</h4>The project shifted direction when the desired photocrosslinking reactions gave very low yields. Instead of reacting with amino acids as intended, the radical intermediate mainly reacted with itself.The team explored different solvents to stabilize the radical, but found that some solvents, such as DMF, were not inert. Instead, the solvent reacted with the photocatalyst or radical species, revealing unexpected solvent activation chemistry.<h4>Why LC-MS was critical</h4>LC-MS became essential because the reaction mixtures were too complex and low-yielding for NMR or GC-MS. High-resolution LC-MS allowed the team to detect minor products, identify photocatalyst modifications, and observe solvent addition products with high confidence.Repka emphasizes that LC-MS was both a qualitative and quantitative tool. It was used quantitatively to measure how much photocatalyst remained after light exposure, and qualitatively to identify degradation products and new reactivity pathways.<h4>Photocatalyst stability workflow</h4>The team developed a systematic workflow to evaluate photocatalyst stability under light exposure. Because catalyst degradation was time-sensitive, reproducibility required strict control of experimental conditions.Key steps included using a glove box, commercial deoxygenated solvents, accurate weighing on a microbalance, controlled light exposure in a photoreactor, and temperature control with a chiller. These precautions helped reduce day-to-day variability and enabled reproducible measurements of catalyst remaining.<h4>Quantifying catalyst remaining by LC-MS</h4>Calibration curves were prepared using pure photocatalyst solutions and LC-MS ion areas. The team worked in the nanomolar range to maintain linearity.Instead of relying only on total ion chromatograms, they used extracted ion chromatograms (EICs) to improve signal-to-noise for the photocatalyst signal. Baseline subtraction was also applied to reduce noise and improve quantitation at low concentrations.Calibration curves and quality control samples were prepared and measured on the same day as the reaction samples, because LC-MS signal intensity can vary significantly from day to day.<h4>Why GC-MS was used later</h4>For demethylation studies, the group moved to GC-MS because the substrates and products were small and volatile enough for gas chromatography. GC-MS was better suited for rapidly screening many reaction conditions, including different photocatalysts, solvents, and oxidants.Instead of generating full calibration curves for every experiment, the team used an internal standard to streamline analysis and determine percent conversion based on relative response factors.<h4>Practical lessons from the project</h4>Repka highlights the importance of careful sample preparation, especially when working with very small quantities of photocatalysts. A high-quality microbalance, stable granite platform, antistatic tools, and aluminum weigh boats improved weighing accuracy and reproducibility.She also argues that mass spectrometry should be a standard part of photoredox method development because it can reveal minor products, support reaction optimization, and provide insights that may be difficult or impossible to obtain by NMR alone.<h4>Final perspective</h4>Beyond the chemistry, Repka emphasizes the importance of student training and mentoring. For her, research is not only about discovering new reactivity but also about giving students practical experience, helping them develop independence, and preparing them for future scientific careers.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

Using LC-MS & GC-MS to Decode Photoredox Catalyst Stability

Article

Application

Video

Scientists

Interview

Science and research

The University of Chemistry and Technology, Prague is a natural centre of first-rate study and research in the area of chemistry in Czechia and is one of the country's largest educational and research institutions focused on technical chemistry, chemical and biochemical technologies, material and chemical engineering, food chemistry, and environmental studies.

UCT Prague

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Technology Networks

Bruker

Thermo Fisher Scientific

SCIEX

Waters Corporation

<h4>Virtual event: Pharma conclave series 2024</h4>
SCIEX offers the platform for the experts to take the stage and drive technological progress
Welcome to Pharma conclave series 2024 – where our customers’ expertise meets innovation, transforming your knowledge and empowering you to revolutionize your work processes. Join us in discovering techniques that will enhance your skills to accelerate your daily operations in the development of new drugs.
From the research of new markers to the drug development moving into non and GLP bioanalysis. Confidently plan your next lab expansion with the knowledge gained from industry leaders and pioneers.
<ul>
<li>May 16 Event 1: Pharma omics</li>
<li>September 17 Event 2: Impurities</li>
<li>October 23-24 Event 3: Pharma</li>
</ul>
10:00 a.m.–12:00 p.m. CET
<h3>Event 2: Impurities</h3>
Impurities in the pharmaceutical industry. What&#39;s next?
While the regulatory landscape is changing faster than ever, having the right information on impurities available to you at every stage of the drug development is vital to bring safe and effective therapies to the market. Whether you want to optimize your lab’s current capabilities or scale up to meet your future demands, this event creates a platform to share the customer’s expertise.
<blockquote>
Presenter: Bruno Manadas, PhD
</blockquote>
<blockquote>
Dr Manadas is a prominent Cell Biology researcher at CNC-UC since 2017. With expertise in biochemistry, psychology, and biotechnology, he&#39;s authored 130+ publications and led multiple projects. As head of CNC&#39;s Mass Spectrometry node and Associate Editor for Frontiers, he&#39;s contributed significantly to neuroscience and psychiatry. Bruno&#39;s research focuses on cell biology mechanisms, translational biomarker research, and MS-based approaches for studying protein oxidation. He played a pivotal role in establishing the hospital biobank and teaches at the Portuguese Catholic University.
</blockquote>
<blockquote>
Presenter: Dorte Bekker-Jensen
</blockquote>
<blockquote>
Dorte is heading the Applications Development team in Proteomics Research at Evosep. She has long-term experience within proteomics and has focused on technology development by developing simple and automated workflows for high-throughput applications.
</blockquote>
<blockquote>
Presenter: Stefan Ledinger
</blockquote>
<blockquote>
Stefan has 20 years of experience in the life sciences and diagnostic industries. For the last dozen years, he has been serving various functions within biocrates life sciences ag. Most recently, he has been responsible for the market development for metabolomics solutions in the pharmaceutical and biotech industries. He currently serves as Global Head of Sales. Stefan holds degrees in business administration and bioengineering, combining commercial know-how with a passion for science.
</blockquote>
<blockquote>
Presenter: Markus Langsdorf
</blockquote>
<blockquote>
Markus has 14 years of experience in life sciences industries. As he joined biocrates in 2010, he worked for 11 years as application support specialist for biocrates’ metabolomics profiling solutions. 3 years ago he changed his position withing the company to his new function as product manager. Markus studied chemistry and graduated with a PhD in Analytical Chemistry.
</blockquote>

Pharma conclave series 2024: Impurities

<h4>Live from the Lab hosted by NIBRT: Solutions for biotherapeutic analysis</h4>
By your side to accelerate your biopharmaceutical development journey
Join us for the second Live from the Lab of 2024, taking place on September 17th, an exciting biopharma hybrid event featuring the latest advancements in separation technology and mass spectrometry. Focusing on all stages of biotherapeutics development, from discovery and research, all the way to routine and QC analysis, this event will give you valuable insights to accelerate your biopharmaceutical development journey.
The following speakers will talk at this event at the NIBRT research facility which will be streamed live all over Europe:
<ul>
<li>Dr. Jonathan Bones, NIBRT</li>
<li>Prof. Mark Dickman, University of Sheffield</li>
<li>Dr. Dan Bach Kristensen, Symphogen</li>
<li>Dr. Mark Hilliard, Pfizer</li>
<li>Dr. Ken Cook, Thermo Fisher Scientific</li>
<li>Jon Bardsley, Thermo Fisher Scientific</li>
</ul>
Whether you are a researcher, scientist, or industry professional in our region, this biopharma event is not to be missed. Expand your knowledge, network with experts, and discover how the Thermo Scientific solutions will stand by your side to accelerate your biopharmaceutical development journey.
Mark your calendars for September 17th and join us for this impactful hybrid event foster collaboration within the scientific community.
Participation is free of charge, registration is required.
For any questions about this event or regarding your registration, please email CMDEvents@thermofisher.com.
<h4>How to attend?</h4>
3 ways of attending:
<h5>Online attendees (remote):</h5>
Unable to travel to a satellite? Not a problem! You can register to attend conveniently online from your desk or anywhere else through the live stream from NIBRT.
<ul>
<li><a href="https://assets.thermofisher.com/TFS-Assets/CMD/Flyers/fl-003119-pb-live-from-the-lab-ms-biotherapeutics-agenda-online-fl003119-em-en.pdf">Agenda</a></li>
</ul>
<h5>NIBRT Research Facility (in-person event):</h5>
Join the heart of the event where the main agenda will be hosted and live streamed across our region to our satellite events and our online audience. Attendance through VIP invitation only!
<h5>Join a ‘Satellite’ location (in-person event):</h5>
Across Europe, our in-person satellite events will be broadcasting the main agenda live streamed from NIBRT, Dublin and supplement the day with local speakers/lab tours pending on the satellite. Take this opportunity to network with fellow scientists and meet your Thermo Fisher representatives from technical, commercial, and service functions. Check out the closest location to you and their individual agenda!
<ul>
<li>Søborg, Denmark (AGC Biologics)</li>
<li>Dreieich, Germany (Thermo Fisher Scientific)</li>
<li>Segrate, Italy (MI) (Thermo Fisher Scientific S.P.A.)</li>
<li>Leiden, Netherlands (Janssen Biologics BV)</li>
<li>Ljubljana, Slovenia (Four Points by Sheraton Ljubljana Mons)</li>
<li>Reinach, Switzerland (Thermo Fisher Scientific)</li>
<li>Hemel Hempstead, UK (Thermo Fisher Scientific)</li>
</ul>

Thermo Fisher Scientific: Live from the Lab: Solutions for biotherapeutics

Live from the Lab: Solutions for biotherapeutics

An exciting biopharma hybrid event featuring the latest advancements in separation technology and mass spectrometry.

The sample throughput of high-sensitivity liquid chromatography-mass spectrometry (LC-MS) based proteomics analysis is restricted by the pressure limitations of LC and column hardware, with some methods wasting as much as 50% of the method cycle time outside of MS acquisition.
Traditional routes for boosting throughput include shorter columns and gradients, higher flow rates, and using trap-and-elute workflows – all of which introduce trade-offs in sensitivity and proteome depth.
The Thermo Scientific™ Vanquish™ Neo tandem direct injection workflow leverages hardware innovations and software intelligence to eliminate method overhead while maintaining data quality across nano, capillary, and micro-flow LC-MS.
In this webinar experts from Evotec and Bayer will showcase how they implemented the tandem direct injection workflow for their proteomics work. Dr. Nagarjuna Nagaraj will present on how Evotec is using tandem direct injection with nano-LC columns packed in-house to boost sample throughput of their chemoproteomics screening pipeline, while Dr. Alexander Boychenko from Bayer will discuss how his lab is using a micro-flow tandem direct injection approach to analyze plasma samples for translational proteomics.
Learning Objectives
<ul>
<li>See how minimizing LC-MS method overhead can accelerate sample throughput while maintaining proteome depth
</li>
<li>Discover how labs are using tandem direct injection for chemoproteomics and translational proteomics applications
</li>
<li>Learn how to implement tandem direct injection in your proteomics workflow
</li>
</ul>
<blockquote>
Presenter: Dr. Nagarjuna Nagaraj (Group Leader High Sensitivity Proteomics, Evotec)
</blockquote>
<blockquote>
Dr. Nagarjuna Nagaraj is a proteomics group leader at Evotec focusing on high sensitivity and high throughput proteomics applications with more than 18 years of experience in proteomics and mass spectrometry. Nagarjuna obtained his PhD from the Matthias Mann lab focusing on sample preparation and MS data acquisition strategies for clinical applications. After a postdoc he directed the mass spectrometry core facility at the Max-Planck-Institute of Biochemistry working on a wide range of protein and peptide mass spectrometry projects such as bottom-up proteomics, structural mass spectrometry including HDX, native and crosslinking MS, intact protein and small molecule analysis.
</blockquote>
<blockquote>
Presenter: Dr. Alexander Boychenko (Head of R&amp;D Laboratory Precision Medicine Markers, Bayer)
</blockquote>
<blockquote>
Alexander Boychenko is leading Omics Research within the Translational Sciences team of the Pharmaceuticals division at Bayer Group. He is focused on implementing innovative analytical technologies and developing novel methodologies for proteomics, metabolomics, and ligand-binding assays (LBA) to comprehensively characterize human and animal model phenotypes, enabling disease understanding and novel biomarker discovery. He holds a Ph.D. in Analytical Chemistry from Kharkiv National University, Ukraine. During his post-doctoral work at the University of Groningen, The Netherlands, he combined LC-MS and immunoassays to discover and validate protein biomarkers in biofluids for cancer screening. Before joining Research and Early Development at Bayer AG, he developed and introduced new liquid chromatography-mass spectrometry products at Thermo Fisher Scientific. Alexander is a subject matter expert in LC-MS, biological data interpretation, and precision medicine. He utilizes his passion for applying technical expertise to develop new medicines.
</blockquote>
<blockquote>
Presenter: Dr. Alec Valenta (Product Marketing Manager, Thermo Fisher Scientific)
</blockquote>
<blockquote>
Alec is the product marketing manager for the Vanquish Neo UHPLC system and low-flow LC columns. Prior to joining Thermo Fisher Scientific he earned his PhD in analytical chemistry from the University of Michigan where he helped advance microdialysis sampling of neurochemicals and developed LC-MS methods to quantify small molecule neurotransmitters, neuropeptides, and metabolites in a variety of complex biological samples.
</blockquote>

Thermo Scientific: A Tandem LC Workflow for Maximizing Mass Spectrometer Utilization in Proteomics

A Tandem LC Workflow for Maximizing Mass Spectrometer Utilization in Proteomics

How experts from Evotec and Bayer implemented the tandem direct injection workflow for their proteomics work.

A Tandem LC Workflow for Maximizing Mass Spectrometer

Join us for an exclusive two-day event where Agilent will showcase cutting-edge biopharma solutions.
The first day of the event we will explore Agilent’s comprehensive portfolio for the spectrum of applications from drug discovery to quality control. Learn more about our cell analysis and genomics expertise and the tools we provide to drive IVT mRNA development, protein therapeutics and cell and gene therapies
The second day will focus on advanced analytical solutions, including HRMS for tRNA sequencing and LC/MS for DNA/RNA analysis. Learn how to scale up oligonucleotide purification with Agilent biocolumns, which enhance the efficiency and accuracy of your processes.
By attending this event you will:
<ul>
<li>Gain insights from Agilent to optimize biotherapeutic workflows, including rigorous quality testing in cGMP environments and handling nucleic acid, vaccines, mAB and protein samples.
</li>
<li>Understand how metabolic analyses can impact CAR cell function and behavior, using cytolytic cell killing assays on the xCELLigence system to develop cell therapy processes and confirm product potency.
</li>
<li>Learn about new techniques in high-resolution LC/MS for analyzing tRNA modifications.
</li>
<li>Discover software tools available for high-resolution MS systems in both research and QA/QC labs.
</li>
<li>Compare analytical and semipreparative LC purification methods for synthetic oligonucleotides, gaining competitive insights into purification strategies.
</li>
</ul>
<h5>Talk 1: Agilent Tools and Technologies to Drive Advancements in Biopharmaceutical Drug Development</h5>
<ul>
<li>Presented by Dr. Hervé Chaulet, Molecular and Biological Research Market Specialist, Agilent Technologies</li>
</ul>
Discovering, developing, and manufacturing biopharmaceuticals requires you to stay abreast of advances in knowledge and improvements in technology while constantly navigating a maze of business and scientific challenges. Agilent can be a trusted partner providing expertise and end-to-end workflows including systems, software, consumables, and services for the spectrum of applications from drug discovery to quality control. Learn more about our cell analysis and genomics expertise and the tools we provide to drive IVT mRNA development, protein therapeutics, and cell and gene therapies.
<h5>Talk 2: Quality Control In IVT mRNA Therapeutics and Vaccine Development Workflow Using The Agilent Fragment Analyzer System</h5>
<ul>
<li>Presented by Dr. Leslie Friedmann, Product Manager, Agilent Technologies</li>
</ul>
Reliable and robust analysis is essential throughout in vitro transcription (IVT) mRNA workflows, providing important quality information to help minimize risk and aid in the production of a consistent product. The Agilent Fragment Analyzer systems can be used for several QC steps at different checkpoints in mRNA vaccine development, providing accurate and precise sizing and integrity analysis. These QC steps are to determine the quality and size of the linearized plasmid, the size and purity of the IVT mRNA, length of the poly(A) tail, and purity of the final mRNA vaccine product.
<h5>Talk 3: Analysis of NIST mAb Reference Material by Parallel SDS-Capillary Electrophoresis</h5>
<ul>
<li>Presented by Dr. Kyle Luttgeharm, Product Manager, Agilent Technologies</li>
</ul>
Monoclonal antibody drug products are complex biomolecules that must be tested for critical quality attributes (CQAs) such as monomeric purity and percent glycosylation. Capillary gel electrophoresis methods have been adopted as the standard method for size heterogeneity characterization, however legacy capillary electrophoresis (CE) methods involve complicated workflows or are cost prohibitive. To address these problems with legacy methods, Agilent has developed a 12-channel, parallel capillary electrophoresis-SDS (CE-SDS) instrument and reagents. The system uses a high-resolution sieving gel, allowing for resolution of mAb species including the non-glycosylated heavy chain and light chain. To demonstrate the capabilities of the ProteoAnalyzer, the NIST mAb was characterized under both reduced and non-reduced conditions and compared to the NIST data sheet.
<h5>Talk 4: Advanced Analytics for Cell Therapy Research, Process Development, and Manufacturing</h5>
<ul>
<li>Presented by Dr. Kelly Kroeger, Science &amp; Technology Advisor, Agilent Technologies</li>
</ul>
With immunology and immune-based therapies rising as a pillar of science and therapeutics, we are seeing a foundational shift from targeting specific proteins and pathways to actually targeting the immune cellular network that resolves and prevents disease. Therefore there is a critical need for cell analysis tools to facilitate understanding of the dynamic nature of the interaction of these cellular networks whether it is in the context of immune cells or immune cells with cancer cells.
To address these new challenges, we at Agilent Technologies have developed a portfolio of cell analysis solutions that provide researchers with more relevant tools to measure living cells, dynamically track them, and model their microenvironments. These next-generation therapies require methods and technologies to enable assessment of real-time cell function, phenotype, and fate. Used together, the Agilent tool bench provides the capability to measure and develop immune cell function more effectively, thus enabling translational researchers and developers to achieve the necessary level of potential therapeutic potency and safety.

Technology Networks: Biopharma Innovations Summit

Biopharma Innovations Summit Day 1

Learn more about our cell analysis and genomics expertise and the tools we provide to drive IVT mRNA development.

Fragmentation-based molecular annotations are the gold standard in high-confidence biomarker identification using mass spectrometry.
The new iprm-PASEF workflow integrates CCS-enabled MALDI Imaging of lipids with a targeted MS/MS imaging approach that allows spatial fragmentation and analysis of multiple targets in a single acquisition. The workflow includes a fully integrated pipeline within our software ecosystem to generate accurate identifications with spatial fidelity.
Key Learning Objectives:
<ul>
<li>Fragmentation based MALDI Imaging capabilities
</li>
<li>iprm-PASEF workflow for the timsTOF fleX
</li>
<li>Fragmentation based annotation pipeline using SCiLS™ Lab
</li>
</ul>
Who should attend:
<ul>
<li>Researchers interested in expanding their spatial biology toolkit
</li>
<li>Researchers focused on maximizing confidence of molecular annotations for MALDI Imaging
</li>
<li>Anyone who wants to expand their MALDI Imaging workflows
</li>
</ul>
<blockquote>
Presenter: Michael Becker, Ph.D. (Principal Scientist DMPK, Boehringer Ingelheim Pharma GmbH &amp; Co KG, Mainz, Germany)
</blockquote>
<blockquote>
Dr. Michael Becker is the head of the Mass Spectrometry Imaging lab at Boehringer Ingelheim. He received his Ph.D. in Neurobiology, and transitioned into the imaging field more than 15 years ago. He uses MSI to study drugs and drug-induced changes in tissue. To do so, he tries to push the sensitivity, reproducibility and specificity of the method.
</blockquote>
<blockquote>
Presenter: Arne Behrens, Ph.D. (Application Specialist in MALDI Imaging, Bruker Daltonics GmbH &amp; Co. KG, Bremen, Germany)
</blockquote>
<blockquote>
Dr. Arne Behrens is an Imaging Applications Scientist  at Bruker in Bremen with more than 6 years of experience on the timsTOF fleX platform. He received his Ph.D. in Analytical Chemistry and is an expert for CCS-enabled MALDI Imaging applications.
</blockquote>
<blockquote>
Presenter: Björn Wendik, Ph.D. (Business Development Manager, Bruker Daltonics GmbH &amp; Co. KG, Bremen, Germany)
</blockquote>
<blockquote>
Björn studied biology at the University of Würzburg and University of Freiburg with focus on developmental biology. In Freiburg he did his Ph.D. working on motoneuron development and pancreas formation. He became an expert on life cell imaging, timelapse studies and 3d-image software analyses. He continued his work as lecturer at the University of Freiburg where he also took care of parts of the Imaging core facility. When stepping into industry, he worked as a specialist for confocal microscopy and from there moved on into multispectral imaging, antibody based multi- and hiplexing and tissue analysis platforms. With this expertise, Björn started as a Business Development Manager for the MALDI Imaging at Bruker in July 2023.
</blockquote>

Bruker: Confidence in spatial identifications using iprm-PASEF on the timsTOF fleX

Confidence in spatial identifications using iprm-PASEF on the timsTOF fleX

The new iprm-PASEF workflow integrates CCS-enabled MALDI Imaging of lipids with a targeted MS/MS imaging approach.

Confidence in spatial identifications using iprm-PASEF

Join us for an exclusive two-day event where Agilent will showcase cutting-edge biopharma solutions.
The first day of the event we will explore Agilent’s comprehensive portfolio for the spectrum of applications from drug discovery to quality control. Learn more about our cell analysis and genomics expertise and the tools we provide to drive IVT mRNA development, protein therapeutics and cell and gene therapies
The second day will focus on advanced analytical solutions, including HRMS for tRNA sequencing and LC/MS for DNA/RNA analysis. Learn how to scale up oligonucleotide purification with Agilent biocolumns, which enhance the efficiency and accuracy of your processes.
By attending this event you will:
<ul>
<li>Gain insights from Agilent to optimize biotherapeutic workflows, including rigorous quality testing in cGMP environments and handling nucleic acid, vaccines, mAB and protein samples.
</li>
<li>Understand how metabolic analyses can impact CAR cell function and behavior, using cytolytic cell killing assays on the xCELLigence system to develop cell therapy processes and confirm product potency.
</li>
<li>Learn about new techniques in high-resolution LC/MS for analyzing tRNA modifications.
</li>
<li>Discover software tools available for high-resolution MS systems in both research and QA/QC labs.
</li>
<li>Compare analytical and semipreparative LC purification methods for synthetic oligonucleotides, gaining competitive insights into purification strategies.
</li>
</ul>
<h5>Talk 1: Advanced Analytical Solutions for Nucleic Acid Analysis and Purification</h5>
<ul>
<li>Presented by Dr. Charlotte Lekieffre, Biopharma Application Specialist, Agilent Technologies</li>
</ul>
The emphasis during the second day of the Summit will be on advanced analytical solutions, such as HRMS for tRNA sequencing and LC/MS for DNA/RNA analysis. Additionally, you’ll discover techniques to enhance the efficiency and accuracy of your processes by scaling up oligonucleotide purification using Agilent biocolumns. 
<h5>Talk 2: Extracted Yeast tRNA Sequencing by LC-MS/MS</h5>
<ul>
<li>Presented by Aurore Attina, Engineer of Mass Spectrometry, University of Montpellier</li>
</ul>
RNA modifications are essential for RNA stability, maturation, and functionality; directly influencing protein translation and gene regulation. They play a central role in various biological processes and are associated with many diseases, including cancers and neurological disorders. tRNA (transfer RNA), which plays a key role in protein synthesis, is the most modified molecule in the organism known to date. tRNA modifications are essential to ensure their correct function in protein translation, maintain the accuracy and fidelity of the genetic code, and enable flexible adaptation to changing cellular conditions and are therefore a crucial attribute to monitor. To monitor and map these modifications of tRNA, we have developed a LC-HRMS analytical workflow, first using synthetic oligonucleotide for the method optimization. In this webinar, we will first go through the various steps involved in LC-MS/MS method optimization using synthetic oligonucleotides. In a second part, we will present the protocol development of an enzymatic digestion applied to tRNA extracted from yeast. This digestion generates oligonucleotide fragments that can be analyzed by LC-MS/MS for sequence confirmation.
<h5>Talk 3: Discover Agilent’s Software Tools to Confirm Oligonucleotide Sequence Integrity</h5>
<ul>
<li>Presented by Dr. Holger Stalz, LC/MS Product Specialist Austria &amp; Switzerland, Agilent Technologies</li>
</ul>
Mass spectrometry (MS) is increasingly important for the development of therapeutic modalities such as oligonucleotides. A common analytical method for large molecules is intact mass by LC/MS. This can be used for the characterization and identification of a product or process-related impurities, or simply as a confirmation of molecular weight. The newly introduced Agilent OpenLab CDS 2.8 SW version comes with a set of features to enable the automatization of biopharma workflows. If you want to know how LC/MSD Spectral Deconvolution of your biopharma samples can be automated, we will provide answers during our presentation. Even more details on Oligonucleotide sequence confirmation and impurities characterization can be acquired using the power of a high-resolution accurate mass system (HRAM) on the Agilent 6545XT AdvanceBio LC/Q-TOF. Analyzing the sample data with the software workflows in Agilent BioConfirm version 12 will support the user to get the trusted answers to their most relevant questions.
<h5>Talk 4 Maximize Your Resources and Simplify Scale-up with AdvanceBio Oligonucleotide Columns</h5>
<ul>
<li>Presented by Dr. Andrea Tripodi, Application Development Engineer, Agilent Technologies</li>
</ul>
Several classes of nucleic acids, such as antisense oligonucleotides, small interfering RNAs (siRNAs), and aptamers are being investigated for potential therapeutic applications. Synthetic oligonucleotides inevitably contain many impurities due to limitations in the efficiency of each chemical reaction used during manufacture. They include deletion sequences (missing one or more nucleotides) and reaction by-products often arising during the final deprotection or cleavage steps. Ion pair reversed-phase (IP-RP) chromatography stands out as the prevalent method for analyzing and purifying oligonucleotides. For increased resolution and separation of your full-length synthetic oligonucleotide from closely related impurities, AdvanceBio Oligonucleotide is the ideal choice. The latest developments include semi-preparative, and lab-scale preparative columns packed with superficially porous particles that provide excellent performance and resolution without compromising column loading. A fast and easy scale-up method from analytical to semi-preparative scale was successfully achieved using a 10 mm ID column enabling higher sample loading using the same analytical LC instrument.

Biopharma Innovations Summit Day 2

<h3>Session #2 - Innovative Approaches in HRMS and Software for PFAS Analysis</h3>We are excited to invite you to our upcoming webinar, where we will explore the latest advancements in PFAS analysis through innovative screening methods and technologies. Our expert speakers will cover various approaches to enhance the detection and identification of per- and polyfluoroalkyl substances (PFAS).<h4>1. Nontarget Screening workflow (NTS) for the Analysis of Per and Polyfluoroalkyl Substances (PFAS) using High resolution mass spectrometry (HRMS)</h4><ul><li>Presented by Hania Khoury-Hollins</li></ul>This session will focus on using HRMS as an effective tool to detect both regulated and non-regulated PFAS. We’ll explore the UNIFI™ screening workflow and discuss the use of comprehensive PFAS libraries to improve detection capabilities.<h4>2. Untargeted Screening for PFAS Chemicals Using Comprehensive Feature Detection</h4><ul><li>Presented by Jeff Goshawk</li></ul>Discover how advanced feature detection methods can identify a wide range of PFAS chemicals, including those not covered by traditional reference standards. This talk will highlight techniques to detect novel PFAS-like chemicals, providing a broader understanding of total organic fluorine content in samples.<h4>3. Elevating Specificity and Identification Confidence for PFAS Liquid Chromatography and Cyclic Ion Mobility Mass Spectrometry</h4><ul><li>Presented by Michael McCullagh</li></ul>Learn how cyclic ion mobility (cIM) enhances the separation and identification of PFAS isomers. By using this method, we can achieve greater specificity and reduce analysis time, providing insights into PFAS exposure and its potential health impacts.Join us to learn how these cutting-edge approaches are revolutionizing PFAS detection and analysis, offering more accurate and efficient solutions for environmental monitoring and public health protection.<blockquote>Presenter: Hania Khoury-Hollins (Principal Scientist, Waters Corporation)Hania Khoury-Hollins is a scientist and researcher at Waters Corporation. She holds a bachelor’s degree in science, which laid the foundation for her scientific pursuits. In 2001, Hania earned her master’s degree in Toxicology, deepening her understanding of the impact of chemicals on living organisms. In 2005 she successfully defended her Ph.D. in physical chemistry from University René Descartes - Paris V (France). After undertaking several different projects in academia Hania spent some time working at Agilent before joining Waters.At Waters, her work revolves around developing cutting-edge analytical techniques and their applications with a focus on Liquid Chromatography coupled with High-Resolution Mass Spectrometry (LC-HRMS). Her expertise encompasses a diverse range of applications, including drug development, proteomics, metabolomics, and lipidomics. More recently, Hania has been developing applications strategies for per- and polyfluoroalkyl substances (PFAS).Presenter:&nbsp;Mike McCullagh (Consulting Scientist, Waters Corporation)Michael has worked at Waters Corporation for over 23 years. His main focus has been non-targeted analysis using time of flight mass spectrometry and ion mobility mass spectrometry. Michael has made contributions to various teams, including Food and Environmental, MS Evaluation, Life Science, Scientific Operations, the Advanced Mass Spectrometry Team and currently in Research, Development and Advanced Testing. Research has been performed across multiple application areas including, impurity profiling, pesticide screening, natural products, food analysis, metabolite identification and more recently non-targeted PFAS analysis. Having worn a number of different “hats”, the common thread has been the privileged opportunity to work with new technologies, new informatics solutions and to collaborate with industry and global collaborative partners, to forge a path to new discoveries and contribute to solutions to analytical challenges across multiple disciplines.Presenter:&nbsp;Jeff Goshawk (Consulting Scientist, Waters Corporation)Jeff is a Consulting Scientist at Waters Corporation and has been with the company for twenty-four years. Jeff started his career at Waters as a software developer working on MassLynx and its associated application managers. Jeff subsequently transitioned into the applications development group where he joined the toxicology team as a Principal Scientist. Jeff is now back in the software development world at Waters, and is currently working on the Pattern Analysis Application.Presenter:&nbsp;Frank L. Dorman, PhD, FRSC (Principal Environmental Market Manager, Waters Corporation)Frank Dorman is currently Senior Business Development Manager for Waters focusing on their global environmental business and, concurrently, Associate Professor (adjunct) in the Department of Biochemistry and Molecular Biology (BMB) at Penn State University in University Park, PA. In his role at Waters, Frank manages the research-focused environmental market, external collaborations and also interfaces with R&amp;D for new product development. Prior to Waters, Frank was employed full-time as a tenure-line Faculty member of Penn State and served as a member of the Graduate Faculty in: Biochemistry, Microbiology and Molecular Biology (BMMB), Chemistry (CHEM) and the Programs in Forensics Science (FRNSC), and Biogeochemistry (BGC). Frank is also a member of the Center for Molecular Toxicology and Carcinogenesis at Penn State. Frank’s scientific interests are in gas and liquid chromatography fundamental characterization, instrumentation and column development, as well and mass spectrometry and atomic spectroscopy as applied to trace analysis in complex sample matrices. This work is directed towards environmental forensics, traditional forensic chemistry and where environmental exposure events may contribute to human disease; an area sometimes referred to as “exposomics”.Prior to joining the faculty at PSU, Frank was at Restek Corporation for 14 years as the Director of Technical Development, and R&amp;D Senior Chemist. During most of this same time, Frank was also an Adjunct Research Professor at Juniata College where he maintained an active undergraduate research program. Prior to that he was at Inchcape Testing Services for 5 years as a Senior Chemist, Organics Section Manager for Sample Preparation and Corporate Methods Development Chemist. As such, Frank has extensive experience in both the Industrial and Academic sectors giving him a relatively rare combination of skills and experience.</blockquote>

Waters Corporation: Innovative Approaches in HRMS and Software for PFAS Analysis

Innovative Approaches in HRMS and Software for PFAS Analysis

Learn how these cutting-edge approaches are revolutionizing PFAS detection and analysis, offering more accurate and efficient solutions.

Day one: Innovation and data insights<ul><li>Discover how to achieve high sensitivity, speed, and resilience when working with large, complex sample sets</li><li>Learn strategies to speed up your covalent protein drug discovery</li><li>Gain insights into accelerating the development of multiple modalities</li><li>Understand the latest advancements in quantitative proteomics with ZT Scan DIA</li><li>Overcome limitations with cutting-edge artificial intelligence quantitation software</li></ul>Agenda-at-a-glanceWelcome and introduction to innovation and data insights&nbsp;&nbsp;&nbsp;&nbsp;Advancing robustness and serviceability of a high-end triple quad mass spectrometer in a high-throughput bioanalytical lab<ul><li>Highly sensitive mass spectrometers allow the advanced bioanalytical labs of today to achieve the LOQ required of potent biologic drugs and provide maximum flexibility in choice of sample prep techniques. However robust mass spectrometers are crucial for several reasons:<ul><li>Aid in ensuring the consistent quantitative performance of an assay</li><li>Effectively allow a lab to meet their project timelines</li><li>Are essential for handling the inherent variability of analyzing diverse molecules and diverse samples required for bioanalysis</li></ul></li></ul>The new fast in drug discovery: a new MS system to study covalent protein drugs<ul><li>The combination of a super-fast sampling interface with the highly sensitive ZenoTOF 7600 system makes it an ideal system for evaluating covalent binding screens. Main findings in our experiments using the Echo® MS+ system:<ul><li>Speed: measurements from a full 384-well plate in 15 min or 1536-well plate in less than one hour</li><li>Precision: low injection volume supports repetitive measurements and time series; capture full kinetic data set in one experiment</li><li>Quality: high data quality allows for full automated processing, delivering immediate hitlist output</li></ul></li></ul>icIEF-UV/MS characterization of charge Isoforms for biotherapeutic products<ul><li>Characterization of icIEF charge isoforms, whether in early product development or associated with licensure filings, is usually achieved through ion exchange (IEX) liquid chromatography coupled with mass spectrometry. icIEF-MS technology has recently emerged to enable the direct characterization of specific species in the icIEF electropherogram, eliminating the need for extensive method development.<ul><li>Discover opportunities to advance core platform technologies with novel characterization approaches</li><li>Hear case studies on understanding molecular structure information</li><li>New approaches to characterizing post-translational modifications of charge isoforms</li></ul></li></ul>Expanding qualitative and quantitative sensitivity for immunopeptidomics using ZT Scan DIA<ul><li>Learn how utilizing a research-grade Zeno-trap time-of-flight LC-MS system can advance current applications in immunopeptidomics and proteomics, including:<ul><li>What is ZT Scan DIA, the technology and how it benefits data acquisition</li><li>Preliminary proteomics and immunopeptidomics results using ZT Scan DIA</li><li>Future applications of immunopeptidomics using ZT Scan DIA</li></ul></li></ul>Artificial intelligence quantitation (AI quant): molecular structure and mass spectral data quality driven processing of high-resolution mass spectrometry for quantitative analysi<ul><li>High-resolution mass spectrometry (HRMS) has long sought to be a viable alternative for quantitative workflows but has been unable to broadly compete, mainly due to the lack of suitable data processing software. In this work we describe:<ul><li>A molecular structure-dependent workflow</li><li>The holistic and user-independent processesing of HRMS data</li><li>The automatic quantification of small drug-like molecules</li></ul></li></ul>Q&amp;A roundtable: innovation and data insights with the experts<ul><li>Moderated by: Jamie Wighton, Senior Director LC-MS Research, SCIEX</li><li>Panelists include:<ul><li>Rathna Veeramachaneni, Director, Biopharma LC-MS/MS, KCAS Bio</li><li>Xiaping He, Senior Scientist, Pfizer</li><li>Markus Stöckli, Senior Principal Scientist, Novartis Institutes for BioMedical Research</li><li>Tony Purcell, Professor, Monash University&nbsp;</li><li>Kevin Bateman, Retired Pharmacokinetics, Pharmacodynamics and Drug Metabolism Expert</li></ul></li></ul><blockquote>Moderator: Jamie Wighton (Senior Director LC-MS Research, SCIEX)Jamie joined SCIEX 20 years ago and has held multiple technical and leadership roles throughout his career at SCIEX. &nbsp;Starting out as an engineer in manufacturing operations, Jamie has since led teams in supply chain, product development, and most recently the research and product applications teams within R&amp;D. Prior to joining SCIEX, Jamie worked at JDS Uniphase as an optical test engineer.Jamie holds a B.Sc. in engineering physics from Queen’s University.Presenter: Rathna Veeramachaneni (Director, Biopharma LC-MS/MS, KCAS Bioanalytical)Presenter: Markus Stöckli, Senior Principal Scientist, Novartis Institutes for BioMedical ResearchPresenter: Xiaoping He, Senior Scientst, PfizerPresenter: Tony Purcell, Professor, Monash UniversityPresenter: Kevin Bateman, Retired Pharmacokinetics, Pharmacodynamics and Drug Metabolism Expert</blockquote>

SCIEX summit Day one: Innovation and data insights

Importance of LC-MS in food and environmental testing, pharmaceutical and biopharmaceutical discovery and development and biomedical and omics research.

<h4>The Waters 2024 Virtual Summer School - An Educational Journey to Master Food &amp; Environmental Analysis</h4>Unlock the full potential of LC-MS techniques with our immersive and educational sessions at the Waters Virtual F&amp;E Late Summer School 2024. From September 24th to 26th, engage with leading experts and discover cutting-edge methods for environmental and food analysis.<h5>Why attend?</h5><ul><li>Comprehensive Learning: Dive deep into advanced LC-MS techniques and gain practical knowledge to enhance your laboratory's analytical capabilities.</li><li>Expert Insights: Learn from industry leaders and gain firsthand experience through detailed modules on chromatography, mass spectrometry, and sample preparation.</li><li>Regulatory Compliance: Stay ahead with the latest insights on EU regulations for PFAS analysis in food and water, ensuring your lab meets stringent standards.</li></ul><h3>Episode #3: Introduction Non-target Screening (NTS) | F&amp;E Summer School - Day 1 - Module 3</h3>Suspect and non-target screening (NTS) are crucial techniques used in various fields, including food analysis, environmental studies, toxicology, and doping analysis. In this overview, we’ll discuss a holistic approach and introduce high-resolution mass spectrometry methods for both Suspect and NTS screening. Topics covered include resolution, accurate mass data, and ion mobility.In an ideal scenario, Suspect screening and non-Target screening are closely interconnected. Prior knowledge about a potential analyte (Suspect) can expedite the non-Target screening process. We’ll briefly explore Suspect screening and how high-resolution mass spectrometry offers identification criteria for confidently identifying suspect compounds.Further, we examine the data gathered for non-target compounds through high-resolution mass spectrometry. In this module we give a concise introduction to the valuable data that can be compiled for assigning structures. In the forthcoming module 4b we will delve into how this data, in conjunction with the tools offered by the waters_connect software, can be conveniently accessed by the user and provide more comprehensive insights.<h5>What you'll learn:</h5><ul><li>What is Screening? (Target/ Suspect &amp; Non-Target Screening)</li><li>Basics of HRMS (Resolution and accurate mass)</li><li>Identification criteria for Targets /Suspects &amp; UNIFI Scientific Library</li><li>Tools for Non-Target Screening</li><li>Short introduction of exemplary instrument types</li><li>Xevo G3 QToF for Routine Screening</li><li>Xevo MRT for Screening with very high-resolution and very high mass accuracy</li><li>Select Series Cyclic IMS for Screening with ion-mobility utilizing CCS-values</li></ul><blockquote>Presenter:&nbsp;Christoph Thomas (Principal Sales Applications Chemist, Waters Corporation)Christoph Thomas is a Principal Sales Applications Chemist from the Central Europe Customer Success Team based in Eschborn, Germany. He has more than 25 years’ experience in the field of Chromatography and Mass Spectrometry and is familiar with several application areas using Quadrupole and Tof instruments. Within the last decade his projects were mainly focused on the waters_connect Screening Solution in food and environmental screening, toxicology screening, metabolite identification and in the field of extractables and leacheables.Presenter:&nbsp;Gunnar Weibchen (Principal MS Sales Dev Specialist, Waters Corporation)Gunnar studied Chemistry and obtained a PhD in Organic and Analytical Chemistry in Hamburg. After working as an Application Chemist in the demo laboratory at Varian, has been with Waters in Sales and Marketing since 2010</blockquote>

Waters Corporation: The Waters 2024 Virtual Summer School

Introduction Non-target Screening (NTS)

We’ll discuss a holistic approach and introduce high-resolution mass spectrometry methods for both Suspect and NTS screening.

<h4>The Waters 2024 Virtual Summer School - An Educational Journey to Master Food &amp; Environmental Analysis</h4>Unlock the full potential of LC-MS techniques with our immersive and educational sessions at the Waters Virtual F&amp;E Late Summer School 2024. From September 24th to 26th, engage with leading experts and discover cutting-edge methods for environmental and food analysis.<h5>Why attend?</h5><ul><li>Comprehensive Learning: Dive deep into advanced LC-MS techniques and gain practical knowledge to enhance your laboratory's analytical capabilities.</li><li>Expert Insights: Learn from industry leaders and gain firsthand experience through detailed modules on chromatography, mass spectrometry, and sample preparation.</li><li>Regulatory Compliance: Stay ahead with the latest insights on EU regulations for PFAS analysis in food and water, ensuring your lab meets stringent standards.</li></ul><h3>Episode #8: Instruments &amp; Software for Non-Target Screening | F&amp;E Summer School - Day 2 - Module 4</h3>This session will focus on presenting in detail the data evaluation of HRMS-Screening experiments. Firstly, we will explain the data-independent acquisition modes MSE and HDMSE. We will describe an intelligent and efficient peak detection algorithm of the HRMS data. The waters_connect software supports us with several tools for the challenging non-Target screening. We will present a selection of discovery tools which collect additional information about the unknown masses to reduce the number of potential candidates. This includes a binary comparison to find differences between samples or the get information on common fragments etc. In addition, multivariate statistics can also be used as a powerful tool for identifying significant non-Target masses. Finally, the determination of the molecular formula of potential candidates and a possible search in online libraries will be presented.<h5>What you'll learn:</h5><ul><li>Data acquisition in depth (MSE, CCS)</li><li>waters_connect Software &amp; Intelligent Peak Detection</li><li>UNIFI App and Workflow</li><li>Binary Compare - find the Differences</li><li>Discovery Tools – Common Fragments, Mass defect filtering, Halogen Match and more</li><li>Multivariate statistics</li><li>Pattern Targeting Application</li></ul><blockquote>Presenter:&nbsp;Christoph Thomas (Principal Sales Applications Chemist, Waters Corporation)Christoph Thomas is a Principal Sales Applications Chemist from the Central Europe Customer Success Team based in Eschborn, Germany. He has more than 25 years’ experience in the field of Chromatography and Mass Spectrometry and is familiar with several application areas using Quadrupole and Tof instruments. Within the last decade his projects were mainly focused on the waters_connect Screening Solution in food and environmental screening, toxicology screening, metabolite identification and in the field of extractables and leacheables.Presenter:&nbsp;Gunnar Weibchen (Principal MS Sales Dev Specialist, Waters Corporation)Gunnar studied Chemistry and obtained a PhD in Organic and Analytical Chemistry in Hamburg. After working as an Application Chemist in the demo laboratory at Varian, has been with Waters in Sales and Marketing since 2010</blockquote>

Software and Instruments for NTS

This session will focus on presenting in detail the data evaluation of HRMS-Screening experiments. 

LCMS webinars focusing on LC/HRMS - page 24